I-FondaparinSodiumM;I-Fondaparinux Sodium Identification;Fondaparinux sodium N-4;
I-FondaparinSodiumM;I-Fondaparinux Sodium Identification;Fondaparinux sodium N-4;
I-Fondaparinux Biological Activity
| Chaza | I-Fondaparinux sodium iyi-antithrombin-dependent factor Xa inhibitor. |
| OkuhlobeneIzigaba | indlela yesignali >> Ama-enzyme/amaphrotheni e-metabolic >> Izindawo zokucwaninga nge-Factor Xa >> Izifo zenhliziyo |
| Ithagethi | I-Factor Xa[1] |
| In vitroizifundo | I-Fondaparinux sodium iyi-anticoagulant yokuqala entsha eqondisa ngokukhetha i-factor Xa.Ku-Fondaparinux, inani le-IC50 (anti-Xa IU/ml) lama-monocyte acushiwe (ac-M) lingu-0.59±0.05, kanye nezinhlayiya ezitholakala ku-monocyte (MMP) ngu-0.17±0.03 [2]. |
| Nge-vivoucwaningo | I-Fondaparinux sodium inephrofayili ye-pharmacokinetic eqondile, encike kumthamo, enikeza impendulo ebikezelwe kakhulu.I-Fondaparinux sodium ine-bioavailability engu-100%, iqala ngokushesha ukusebenza, inesigamu sempilo yamahora angu-14 kuya kwangu-16, futhi ingaqhubeka nokumelana ne-thrombosis phakathi namahora angu-24.Umuthi asithinti isikhathi se-prothrombin noma isikhathi esicushiwe se-thromboplastin, futhi asithinti ukusebenza kweplatelet noma ukuhlanganisa [1]. |
| Izithenjwa | [1].Bauer KA.et al.I-Fondaparinux sodium: inhibitor ekhethiwe ye-factor Xa.Am J Health Syst Pharm.2001 Nov 1;58 Isengezo 2:S14-7.[2].Ben-Hadj-Khalifa S, et al.Umphumela ohlukile we-coagulation inhibitory we-fondaparinux, i-enoxaparin ne-heparin engahlukanisiwe kumamodeli wamaseli esizukulwane se-thrombin.Igazi Coagul Fibrinolysis.2011 Jul;22(5):369-73. |
Izakhiwo zamakhemikhali nezomzimba ze-Fondaparinux
| Ifomula yamangqamuzana | I-C31H53N3Na10O49S8 |
| Isisindo samangqamuzana | 1738.16 |
| I-PSA | 900.82000 |
I-Fondaparinux iwuhlobo olusha lomuthi we-antithrombotic ogunyazwe yi-FDA ngemuva kwe-heparin kanye ne-heparin yesisindo esiphansi samangqamuzana okwelapha nokuvimbela izinhlobonhlobo ze-arteriovenous thrombosis.
Izinkomba: I-Fondaparinux isetshenziselwa iziguli ezihlinzwa kakhulu ngamathambo ezitho ezingezansi, njengokuphuka kwe-hip, ukuhlinzwa okukhulu kwamadolo noma ukushintshwa kwe-hip, ukuvimbela i-venous thromboembolism.Isetshenziselwa ukwelapha iziguli ezine-angina engazinzile noma i-non-segment elevation myocardial infarction ezithola ukwelashwa okuphuthumayo (ngaphansi kwemizuzu engu-120) (PCI) ngaphandle kwenkomba.Isetshenziselwa ukwelapha iziguli ezine-ST-segment elevation myocardial infarction ezisebenzisa i-thrombolysis noma ekuqaleni ezingatholi ezinye izinhlobo zokwelapha kabusha.
1）Ukuphromotha kwemakethe okuqhubekayo kuka-Glaxo kuzoyibeka endaweni eyinhloko yezidakamizwa endleleni elandelayo yomtholampilo yoMnyango Wezempilo, ukuguqulwa kwamanani entengo yeKhomishini Kazwelonke Yokuthuthukiswa Nezinguquko, kanye nomshwalense wezokwelapha woMnyango Wezomshuwalense Wabantu.
A, Umkhiqizo awukakangeni kumshwalense wezempilo kazwelonke.Ngo-2010, ukulungiswa komshwalense wezokwelapha kusanda kungena kumshwalense wendawo wezokwelapha wezifundazwe eziyi-16.Ukuthengisa kusesigabeni sokuqala futhi kancane kancane kuzongena esikhundleni semakethe ye-heparin enesisindo esiphansi;izifundazwe zomshuwalense wezokwelapha: Shaanxi, Shanxi, Inner Mongolia, Liaoning, Tibet, Yunnan, Guangdong , Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.
B, Izinkomba zisakhula.I-GSK njengamanje inezinkomba ezi-3 emtholampilo.Isibonelo, izinkomba zama-stents zigunyazwe kuphela.Amanye ama-heparin awatholakali.Ukusetshenziswa komtholampilo kwama-stents kukhuphuka ngo-30% njalo ngonyaka.Ngokugunyazwa kwezinkomba ezintsha, ukuthengisa kuzokhula.Ngokombono, zonke izifo eziphathwa ngemikhiqizo yochungechunge lwe-heparin zingelashwa yilo mkhiqizo.
C、Inzuzo yentengo, inani elincane lentengo yalo mkhiqizo emakethe yase-US ingamadola ayi-132 lilinye, eChina lingu-168 yuan, intengo yasekhaya ngeke yehle.Uma uthumela ngaphandle, imakethe yamazwe ngamazwe inendawo ebanzi;
2) Umkhawulo wezobuchwepheshe uphakeme, impahla eluhlaza ihlanganiswa ngezinyathelo ezingu-75, futhi ilungelo lobunikazi liphelelwe yisikhathi iminyaka engu-5 (i-athikili ngo-2014).Ayigunyazwanga abanye abakhiqizi.I-synthesis inzima kakhulu.Ngeke kwenziwe ngaphansi kweminyaka eyi-10.Umjikelezo mude, unzima, futhi utshale imali.phezulu.Bambalwa abancintisana nabo basekhaya, futhi izimbangi zakwamanye amazwe zinezindleko eziphezulu zempahla eluhlaza.Umgomo wethu uwukunciphisa ngokuqhubekayo izindleko zempahla eluhlaza futhi esikhundleni se-Glaxo ekukhiqizeni impahla eluhlaza.
I-Hengrui Pharmaceuticals Fondaparinux yavunywa njengokulingisa kokuqala e-China 2018.
I-Guangdong Runxing Biotechnology Co., Ltd. inomkhiqizo wonyaka wama-210 kg we-fondaparinux sodium advanced intermediate N3, ezofakwa ngo-2018.
I-Fondaparinux ekuqaleni yasungulwa yi-MYLAN IRELAND.Njengamanje, i-Hengrui Pharmaceuticals, i-Borui Pharmaceuticals, i-Haisco.
I-JIN DUN Medical ineIziqu ze-ISO futhi ihlangabezana namazinga okukhiqiza e-GMP, kuqashwe ochwepheshe basekhaya nabangaphandle abanolwazi olunzulu lokuqondisa i-R&D yenkampani.
TECHNOL OGY UBUHLE
●I-High Pressure Catalytic Hydrogenation.I-High Pressure Hydrogenolysis Reaction .Ukusabela kwe-Cryogenic (<-78%C)
● I-Aromatic Heterocyclic Synthesis
●Ukusabela Kabusha
●Chiral Resolution
●Heck, Suzuki,Negishi,Sonogashira .Ukusabela kukaGiignard
Izisetshenziswa
Ilebhu yethu inezinsiza ezihlukahlukene zokuhlola nokuhlola, njenge: NMR (Bruker 400M), HPLC、chiral-HPLC、LC-MS、LC-MS/MS (API 4000),IR,UV,GC,GC,GC-MS, Chromatography, I-Microwave Synthesizer, i-Parallel Synthesizer, i-Differential Scanning Calorimeter (DSC), i-Electron Microscope...
Ithimba le-R&D
I-Jindun Medical ineqembu labasebenzi abangochwepheshe be-R&D, futhi isebenzisa ochwepheshe abaningi bokwenziwa kwezidakamizwa basekhaya nabangaphandle ukuze baqondise i-R&D, okwenza ukuhlanganiswa kwethu kunembe kakhudlwana futhi kusebenze kahle.
Sisize izinkampani ezimbalwa eziphezulu zasekhaya ezithaka imithi, njengeI-Hansoh, i-Hengrui ne-HEC Pharm.Lapha sizokhombisa ingxenye yazo.
Ikesi Lokwenza Ngokwezifiso:
Inombolo yeCas: 110351-94-5
Ikesi Lokwenza Ngokwezifiso:
Inombolo yeCas: 144848-24-8
Ikesi Lesithathu Lokwenza Ngokwezifiso:
Inombolo yeCas: 200636-54-0
1.Enza ngendlela oyifisayo i-New Intermediates noma ama-API.Ngokufanayo nokwabelana kwecala elingenhla, amakhasimende anezidingo ze-Intermediates ethile noma ama-API, futhi awakwazi ukuthola imikhiqizo edingekayo emakethe, lapho-ke singasiza Ukwenza Ngokwezifiso.
2.Ukuthuthukisa Inqubo Yemikhiqizo Emidala.Ithimba lethu lizosiza Ukuthuthukisa futhi lithuthukise ukukhiqiza okunjalo okuyindlela yokusabela endala, izindleko zokukhiqiza ziphezulu, nokusebenza kahle kuphansi.Singahlinzeka ngemibhalo egcwele yokudluliswa kobuchwepheshe kanye nokuthuthukiswa kwenqubo, sisize ikhasimende ngokukhiqiza okuphumelelayo.
Ukusuka kokuhlosiwe kwezidakamizwa kuye kuma-IND, i-JIN DUN Medical ikunikezaizixazululo zomuntu siqu ze-R&D zokuma okukodwa.
I-JIN DUN Medical iphikelela ekwakheni iqembu elinamaphupho, ukwenza imikhiqizo enesizotha, ecophelelayo, eqinile, futhi siphume konke ukuze sibe uzakwethu othembekile nomngane wamakhasimende!
